Graeber G M, Snyder R J, Fleming A W, Head H D, Lough F C, Parker J S, Zajtchuk R, Brott W H
Ann Thorac Surg. 1982 Dec;34(6):664-73. doi: 10.1016/s0003-4975(10)60906-x.
One hundred ten patients with primary chest wall neoplasms were analyzed for long-term results. The diagnosis of 59 malignant and 51 benign tumors was confirmed by the Armed Forces Institute of Pathology. No deaths were associated with primary definitive therapy. Among the five most frequently encountered malignant tumor types, five-year survivals were obtained in 9 of 17 (53%) patients with fibrosarcoma, 8 of 9 (89%) patients with chondrosarcoma, 2 of 8 (25%) patients with solitary chest wall plasmacytoma (multiple myeloma), 1 of 6 (17%) patients with Ewing's sarcoma, and 2 of 4 (50%) of patients with osteogenic sarcoma. Although the five-year survival appears to indicate therapeutic success in patients with Ewing's sarcoma and osteogenic sarcoma, patients with chondrosarcoma or fibrosarcoma may have a more protracted course, and those with solitary plasmacytoma usually develop multiple myeloma. The findings suggest that radical surgical excision is the treatment of choice for chondrosarcoma; radical surgical excision combined with chemotherapy, for fibrosarcoma and osteogenic sarcoma; surgical excision combined with radiation and chemotherapy, for Ewing's sarcoma; and systemic surveillance and therapy, for pathologically confirmed solitary plasmacytoma.
对110例原发性胸壁肿瘤患者的长期结果进行了分析。59例恶性肿瘤和51例良性肿瘤的诊断经武装部队病理研究所确认。初次确定性治疗未导致死亡。在五种最常见的恶性肿瘤类型中，17例纤维肉瘤患者中有9例（53%）存活5年，9例软骨肉瘤患者中有8例（89%）存活5年，8例孤立性胸壁浆细胞瘤（多发性骨髓瘤）患者中有2例（25%）存活5年，6例尤因肉瘤患者中有1例（17%）存活5年，4例骨肉瘤患者中有2例（50%）存活5年。虽然5年生存率似乎表明尤因肉瘤和骨肉瘤患者的治疗取得了成功，但软骨肉瘤或纤维肉瘤患者的病程可能更长，而孤立性浆细胞瘤患者通常会发展为多发性骨髓瘤。研究结果表明，根治性手术切除是软骨肉瘤的首选治疗方法；根治性手术切除联合化疗是纤维肉瘤和骨肉瘤的治疗方法；手术切除联合放疗和化疗是尤因肉瘤的治疗方法；对于病理确诊的孤立性浆细胞瘤，则采用全身监测和治疗。
